Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Engineering Chimeric Antigen Receptors (CARs) for Solid Tumor Targeting in Cell Therapy

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Engineering Chimeric Antigen Receptors (CARs) for Solid Tumor Targeting in Cell Therapy

Vector & Plasmid Design for Advanced Therapeutic Constructs

CELL & GENE | RNA | BIOLOGICS

Executive Summary

The efficacy and manufacturability of a viral vector program are determined long before the first batch is produced. The architectural design of the plasmid DNA and the selection of the vector backbone are foundational decisions that dictate expression levels, manufacturing titers, and the ultimate safety profile. This service provides direct access to our scientific leadership for consultation on transgene optimization, promoter and polyadenylation signal selection, and the implementation of safety features like self-inactivating (SIN) designs, ensuring your construct is built for a scalable GxP environment from day one.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

Frequently Asked Questions

    What are the primary considerations for plasmid design when developing a lentiviral vector for a complex transgene?

    The architecture of the transfer plasmid is a primary determinant of performance. Key elements include the selection of a promoter appropriate for the target tissue and desired expression kinetics, the inclusion of a Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) to enhance transgene expression, and the choice of a robust polyadenylation signal. For clinical applications, a SIN long terminal repeat (LTR) design is a standard safety requirement.

    How does vector backbone selection impact downstream manufacturing?

    The choice between vector systems like lentivirus or adeno-associated virus (AAV) has significant implications for the manufacturing platform. Each system has distinct requirements for cell culture (adherent vs. suspension), purification strategies, and scalability. Aligning the vector backbone with a well-established and scalable production process early in development prevents costly delays and process redevelopment later on.

    Which analytical assays are necessary to characterize a novel vector construct?

    A robust analytical package is required to define product quality. Core assays include quantifying the vector genome titer (e.g., by ddPCR), assessing the integrity of the packaged genome via Next-Generation Sequencing (NGS), and determining the purity of the preparation by measuring the ratio of full to empty capsids (for AAV) and host cell protein residuals. Functionally, a product-specific potency assay is also developed to measure biological activity.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

The Plasmid Architecture Challenge

The increasing complexity of therapeutic payloads places significant demands on the design of the plasmid DNA used as starting material. A poorly designed plasmid can lead to low vector titers, genetic instability during production, or suboptimal transgene expression in the target cell. Our consultative approach focuses on the molecular architecture of the construct to mitigate these risks.

Key design elements we address include:

  • Promoter & Enhancer Selection: Matching the promoter to the target tissue and desired duration of expression.

  • Transgene Optimization: Codon optimization and removal of cryptic splice sites to ensure stable expression.

  • Polyadenylation Signals: Selection of strong poly(A) signals to maximize mRNA stability and translation.

  • Safety Features: Implementation of SIN backbones for lentiviral vectors to minimize the risk of insertional mutagenesis.

Aligning Vector Design with Manufacturing Readiness

An optimal vector construct is one that can be manufactured reliably at scale. Early-stage decisions on vector serotype (for AAV) or envelope (for lentivirus) must be made in the context of an established, scalable production platform. Proactive planning prevents common downstream bottlenecks, such as production platforms that fail to scale or purification processes that yield inconsistent results. This early alignment is a core component of our Strategic Design Guidance Accelerating Development Lifecycles, which helps programs progress toward an IND submission on an 18-24 month timeline.

Our >100,000 sq ft facility is equipped with multiple adherent and suspension-based platforms to support a wide range of vector programs.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Featured Video: Franklin BioLab Facility Tour

This site tour showcases Franklin Biolabs’ preclinical and bioanalytical facilities, spanning >100k sq ft of animal housing and specialized laboratory space.

Mitigating Immunogenicity Through Vector Design

Managing the host immune response to a viral vector is a well-documented challenge in the field. While immunosuppressive regimens can be effective, as demonstrated by studies showing improved outcomes with prophylactic treatment (PMID: 37833563), vector design itself offers a complementary path to reducing immunogenicity. Strategic modifications to the vector capsid or the transgene cassette can be employed to eliminate immunodominant epitopes. This molecular-level de-risking, combined with a deep understanding of the vector’s interaction with the immune system, provides a more comprehensive strategy for improving the safety and durability of the therapeutic effect.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

Technical Visualization: Vector & Plasmid Design Workflow

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities